"1210-7883" . "351463" . . . "N, V" . "V\u00FDznam magnetick\u00E9 rezonance v diagnostice karcinomu prostaty a prvn\u00ED zku\u0161enosti s vyu\u017Eit\u00EDm MR spektroskopie" . . "RIV/00023884:_____/09:#0003367!RIV12-MZ0-00023884" . "Hor\u00E1k, Martin" . "CZ - \u010Cesk\u00E1 republika" . . "[C2CC625AF763]" . "V\u00FDznam magnetick\u00E9 rezonance v diagnostice karcinomu prostaty a prvn\u00ED zku\u0161enosti s vyu\u017Eit\u00EDm MR spektroskopie"@cs . "1" . "prostate carcinoma, MR imaging, MR spectroscopy, DWI"@en . "4"^^ . "\u010Cesk\u00E1 radiologie" . . "V\u00FDznam magnetick\u00E9 rezonance v diagnostice karcinomu prostaty a prvn\u00ED zku\u0161enosti s vyu\u017Eit\u00EDm MR spektroskopie"@cs . "C\u00CDL: Posoudit mo\u017Enosti diagnostiky karcinomu prostaty s vyu\u017Eit\u00EDm nov\u00FDch metod magnetick\u00E9 rezonance. METODA: Retrospektivn\u011B byla hodnocena MR vy\u0161et\u0159en\u00ED mal\u00E9 p\u00E1nve se zam\u011B\u0159en\u00EDm na prostatu proveden\u00E9 v obdob\u00ED leden 2006 a\u017E \u00FAnor 2008. U v\u0161ech pacient\u016F bylo do z\u00E1kladn\u00EDho protokolu za\u0159azeno dif\u00FAzn\u011B v\u00E1\u017Een\u00E9 zobrazen\u00ED, u \u010D\u00E1sti pacient\u016F bylo provedeno nav\u00EDc spektroskopick\u00E9 m\u011B\u0159en\u00ED. V\u0161echna vy\u0161et\u0159en\u00ED byla provedena na stroji 1,5T s pou\u017Eit\u00EDm body a spine c\u00EDvky. Endorekt\u00E1ln\u00ED c\u00EDvka nebyla pou\u017E\u00EDv\u00E1na. V\u00DDSLEDKY: Ze 48 pacient\u016F z karcinomem prostaty se u 25 pacient\u016F (52,1%) jednalo o T2 stadium, T3a stadium bylo u 8 pacient\u016F (16,7%), T3b u 11 pacient\u016F (22,9%) a u 4 pacient\u016F \u0161lo o pokro\u010Dil\u00FD n\u00E1lez T4 stadium (8,3%). Magnetick\u00E1 rezonance byla prov\u00E1d\u011Bna p\u0159edev\u0161\u00EDm s c\u00EDlem up\u0159esn\u011Bn\u00ED stagingu a pro pl\u00E1nov\u00E1n\u00ED radioterapie, u n\u011Bkolika pacient\u016F bylo vy\u0161et\u0159en\u00ED provedeno s c\u00EDlem prim\u00E1rn\u00ED detekce tumoru po p\u0159edchoz\u00EDch n\u011Bkolika negativn\u00EDch biopsi\u00EDch. Z\u00C1V\u011AR: Dopln\u011Bn\u00EDm prost\u00E9ho MR zobrazov\u00E1n\u00ED o DWI a MR spektroskopii doch\u00E1z\u00ED k roz\u0161\u00ED\u0159en\u00ED metody o informace t\u00FDkaj\u00EDc\u00ED se bun\u011B\u010Dn\u00E9ho metabolismu org\u00E1nu \u010Di tk\u00E1n\u011B."@cs . "PURPOSE: To evaluate options of the prostate carcinoma diagnostics with taking advantage of new Magnetic Resonance methods. METHODE: Magnetic Resonance imaging (MR) of pelvis with a view to prostate performed between January 2006 and February 2008 was evaluate retrospectively. Diffusion-weighted imaging (DWI) was incorporated into basic MR protocol in all patients. MR spectroscopy was used in part of patients group. Examinations were done on 1,5T machine with body and spine coil. Endorectal coil wasn t used. RESULTS: 48 patients with prostate carcinoma 25 patients (52,1%) had T2 stadium, 8 patients (16,7%) had T3a stadium and T3b stadium had 11 patients (22,9%). 4 patients had advanced T4 stadium. MR was carried out for the purpose of staging preciseness and radiotherapy planning. MR examination was performed in several patients for primary tumour detection after previous negative biopsies. SUMMARY: Combination of the MR imaging, DWI and MR spectroscopy allows widening of received information of cell and tissue metabolism."@en . "6"^^ . . "1"^^ . "63" . . "C\u00CDL: Posoudit mo\u017Enosti diagnostiky karcinomu prostaty s vyu\u017Eit\u00EDm nov\u00FDch metod magnetick\u00E9 rezonance. METODA: Retrospektivn\u011B byla hodnocena MR vy\u0161et\u0159en\u00ED mal\u00E9 p\u00E1nve se zam\u011B\u0159en\u00EDm na prostatu proveden\u00E9 v obdob\u00ED leden 2006 a\u017E \u00FAnor 2008. U v\u0161ech pacient\u016F bylo do z\u00E1kladn\u00EDho protokolu za\u0159azeno dif\u00FAzn\u011B v\u00E1\u017Een\u00E9 zobrazen\u00ED, u \u010D\u00E1sti pacient\u016F bylo provedeno nav\u00EDc spektroskopick\u00E9 m\u011B\u0159en\u00ED. V\u0161echna vy\u0161et\u0159en\u00ED byla provedena na stroji 1,5T s pou\u017Eit\u00EDm body a spine c\u00EDvky. Endorekt\u00E1ln\u00ED c\u00EDvka nebyla pou\u017E\u00EDv\u00E1na. V\u00DDSLEDKY: Ze 48 pacient\u016F z karcinomem prostaty se u 25 pacient\u016F (52,1%) jednalo o T2 stadium, T3a stadium bylo u 8 pacient\u016F (16,7%), T3b u 11 pacient\u016F (22,9%) a u 4 pacient\u016F \u0161lo o pokro\u010Dil\u00FD n\u00E1lez T4 stadium (8,3%). Magnetick\u00E1 rezonance byla prov\u00E1d\u011Bna p\u0159edev\u0161\u00EDm s c\u00EDlem up\u0159esn\u011Bn\u00ED stagingu a pro pl\u00E1nov\u00E1n\u00ED radioterapie, u n\u011Bkolika pacient\u016F bylo vy\u0161et\u0159en\u00ED provedeno s c\u00EDlem prim\u00E1rn\u00ED detekce tumoru po p\u0159edchoz\u00EDch n\u011Bkolika negativn\u00EDch biopsi\u00EDch. Z\u00C1V\u011AR: Dopln\u011Bn\u00EDm prost\u00E9ho MR zobrazov\u00E1n\u00ED o DWI a MR spektroskopii doch\u00E1z\u00ED k roz\u0161\u00ED\u0159en\u00ED metody o informace t\u00FDkaj\u00EDc\u00ED se bun\u011B\u010Dn\u00E9ho metabolismu org\u00E1nu \u010Di tk\u00E1n\u011B." . . . . . . . "Use of MR spectrosopy in diagnostics of prostate cancer and our first experience with MRS"@en . "Use of MR spectrosopy in diagnostics of prostate cancer and our first experience with MRS"@en . . . . "RIV/00023884:_____/09:#0003367" . "V\u00FDznam magnetick\u00E9 rezonance v diagnostice karcinomu prostaty a prvn\u00ED zku\u0161enosti s vyu\u017Eit\u00EDm MR spektroskopie" .